Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Intracerebral Hemorrhage

In brief

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.

Key facts

Study ID

NCT03496883

Run by

Joseph Broderick, MD

People needed

860

Starts

2021-12-03

Expected to finish

2028-01-01

Last updated by the study team

2026-01-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18-80 years, inclusive
• Patients with spontaneous ICH
• Able to treat with study medication (rFVIIa/placebo) within 120 minutes of stroke onset or last known well
• Efforts to obtain informed consent per EFIC guidelines (U.S.) or adherence to country-specific emergency research informed consent regulations (Canada, Germany, Spain, U.K., Japan)

You may not qualify if…

• Score of 3 to 7 on the Glasgow Coma Scale
• Secondary ICH related to known causes (e.g., trauma, aneurysm, arteriovenous malformation (AVM), oral anticoagulant use (vitamin K antagonists or novel oral anticoagulants) within the past 7 days, coagulopathy, etc.)
• ICH volume < 2 cc or ≥ 60 cc
• Blood filling 2/3 or more of one lateral ventricle of the brain, OR, blood filling at least 1/3 of both lateral ventricles.
• Pre-existing disability (mRS > 2)
• Symptomatic thrombotic or vaso-occlusive disease in past 90 days (e.g., cerebral infarction, myocardial infarction, pulmonary embolus, deep vein thrombosis, or unstable angina)
• Clinical or EKG evidence of ST elevation consistent with acute myocardial ischemia
• Brainstem location of hemorrhage (patients with cerebellar hemorrhage may be enrolled)
• Refusal to participate in study by patient, legal representative, or family member
• Known or suspected thrombocytopenia (unless current platelet count documented above 50,000/μL)
• Unfractionated heparin use with abnormal PTT
• Pro-coagulant drugs within 24 hours prior to patient enrollment into the FASTEST trial (example, tranexamic acid or aminocaproic acid)
• Low-molecular weight heparin use within the previous 24 hours
• Recent (within 90 days) carotid endarterectomy or coronary or cerebrovascular angioplasty or stenting
• Advanced or terminal illness or any other condition the investigator feels would pose a significant hazard to the patient if rFVIIa were administered
• Recent (within 30 days) participation in any investigational drug or device trial or earlier participation in any investigational drug or device trial for which the duration of effect is expected to persist until to the time of FASTEST enrollment
• Planned withdrawal of care or comfort care measures
• Patient known or suspected of not being able to comply with trial protocol (e.g., due to alcoholism, drug dependency, or psychological disorder)
• Known or suspected allergy to trial medication(s), excipients, or related products
• Contraindications to study medication
• Previous participation in this trial (previously randomized)
• Females of childbearing potential who are known to be pregnant or within 12 weeks post-partum and/or lactating at time of enrollment

Where it is running

• St. Joseph's Hospital and Medical Center — Phoenix, Arizona, United States
• Kaiser Permanente Baldwin Park Medical Center — Baldwin Park, California, United States
• Mills Peninsula Medical Center — Burlingame, California, United States
• Kaiser Permanente Downey Medical Center — Downey, California, United States
• Kaiser Permanente Fontana Medical Center — Fontana, California, United States
• Kaiser Permanente South Bay Medical Center — Harbor City, California, United States
• UCSD Health La Jolla — La Jolla, California, United States
• Kaiser Permanente Los Angeles Medical Center — Los Angeles, California, United States
• Kaiser Permanente West Los Angeles Medical Center — Los Angeles, California, United States
• Ronald Reagan UCLA Medical Center — Los Angeles, California, United States
• UC Irvine Medical Center, — Orange, California, United States
• Kaiser Permanente Riverside Medical Center — Riverside, California, United States
• UC Davis Medical Center — Sacramento, California, United States
• UCSD Medical Center - Hillcrest Hospital — San Diego, California, United States
• San Francisco General Hospital — San Francisco, California, United States
• UF Health Shands Hospital — Gainesville, Florida, United States
• Mayo Clinic — Jacksonville, Florida, United States
• Grady Memorial Hospital — Atlanta, Georgia, United States
• WellStar Kennestone Hospital — Marietta, Georgia, United States
• The Queen's Medical Center — Honolulu, Hawaii, United States
• Northwestern Memorial Hospital — Chicago, Illinois, United States
• University of Chicago Medical Center — Chicago, Illinois, United States
• Central DuPage Hospital — Winfield, Illinois, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• University of Alabama Hospital — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.